{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:32:14Z","timestamp":1791685934311,"version":"4.3.4"},"update-to":[{"DOI":"10.1371\/journal.pntd.0010497","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000}}],"reference-count":75,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["224190\/Z\/21\/Z"],"award-info":[{"award-number":["224190\/Z\/21\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R015600\/1"],"award-info":[{"award-number":["MR\/R015600\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R015600\/1"],"award-info":[{"award-number":["MR\/R015600\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Albendazole is an orally administered anti-parasitic medication with widespread usage in a variety of both programmatic and clinical contexts. Previous work has shown that the drug\u2019s pharmacologically active metabolite, albendazole sulfoxide, is characterised by substantial inter-individual pharmacokinetic variation. This variation might have implications for the efficacy of albendazole treatment, but current understanding of the factors associated with this variation remains incomplete.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methodology\/Principal findings<\/jats:title>\n                    <jats:p>We carried out a systematic review to identify references containing temporally disaggregated data on the plasma concentration of albendazole and\/or (its pharmacologically-active metabolite) albendazole sulfoxide following a single oral dose. These data were then integrated into a mathematical modelling framework to infer albendazole sulfoxide pharmacokinetic parameters and relate them to characteristics of the groups being treated. These characteristics included age, weight, sex, dosage, infection status, and whether patients had received a fatty meal prior to treatment or other drugs alongside albendazole. Our results highlight a number of factors systematically associated with albendazole sulfoxide pharmacokinetic variation including age, existing parasitic infection and receipt of a fatty meal. Age was significantly associated with variation in albendazole sulfoxide systemic availability and peak plasma concentration achieved; as well as the clearance rate (related to the half-life) after adjusting for variation in dosage due to differences in body weight between children and adults. Receipt of a fatty meal prior to treatment was associated with increased albendazole sulfoxide systemic availability (and by extension, peak plasma concentration and total albendazole sulfoxide exposure following the dose). Parasitic infection (particularly echinococcosis) was associated with altered pharmacokinetic parameters, with infected populations displaying distinct characteristics to uninfected ones.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions\/Significance<\/jats:title>\n                    <jats:p>These results highlight the extensive inter-individual variation that characterises albendazole sulfoxide pharmacokinetics and provide insight into some of the factors associated with this variation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pntd.0010497","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T13:27:01Z","timestamp":1666963621000},"page":"e0010497","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":22,"title":["Factors associated with variation in single-dose albendazole pharmacokinetics: A systematic review and modelling analysis"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5003-2575","authenticated-orcid":true,"given":"Charles","family":"Whittaker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric B.","family":"Chesnais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien D. S.","family":"Pion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kamgno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Gloria","family":"Bas\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Boussinesq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"pntd.0010497.ref001","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1136\/jnnp.2008.144899","article-title":"Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial","volume":"79","author":"A Carpio","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"pntd.0010497.ref002","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1128\/AAC.37.8.1679","article-title":"Therapy of human hydatid disease with mebendazole and albendazole","volume":"37","author":"A Teggi","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"pntd.0010497.ref003","doi-asserted-by":"crossref","first-page":"e0007471","DOI":"10.1371\/journal.pntd.0007471","article-title":"Therapeutic efficacy of albendazole against soil-transmitted helminthiasis in children measured by five diagnostic methods","volume":"13","author":"J Vlaminck","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0010497.ref004","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1473-3099(17)30175-5","article-title":"Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo","volume":"17","author":"SDS Pion","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"pntd.0010497.ref005","first-page":"CD003753","article-title":"Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis","volume":"1","author":"CL Macfarlane","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"pntd.0010497.ref006","doi-asserted-by":"crossref","first-page":"e0008298","DOI":"10.1371\/journal.pntd.0008298","article-title":"Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: results from a two-armed, open-label, cluster-randomized, community study","volume":"14","author":"CL Dubray","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0010497.ref007","doi-asserted-by":"crossref","first-page":"e696","DOI":"10.1371\/journal.pntd.0000696","article-title":"Lymphatic filariasis control in Tanzania: effect of repeated mass drug administration with ivermectin and albendazole on infection and transmission","volume":"4","author":"PE Simonsen","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0010497.ref008","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/infdis\/168.1.202","article-title":"Albendazole in human loiasis: results of a double-blind, placebo-controlled trial","volume":"168","author":"AD Klion","year":"1993","journal-title":"J Infect Dis"},{"key":"pntd.0010497.ref009","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1086\/598654","article-title":"Albendazole therapy for loiasis refractory to diethylcarbamazine treatment","volume":"29","author":"AD Klion","year":"1999","journal-title":"Clin Infect Dis"},{"key":"pntd.0010497.ref010","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4269\/ajtmh.17-0664","article-title":"Case report: probable case of spontaneous encephalopathy due to loiasis and dramatic reduction of Loa loa microfilaraemia with prolonged repeated courses of albendazole","volume":"99","author":"DB Arrey-Agbor","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0010497.ref011","doi-asserted-by":"crossref","first-page":"e0004492","DOI":"10.1371\/journal.pntd.0004492","article-title":"Effect of two or six doses 800 mg of albendazole every two months on Loa loa microfilaraemia: a double blind, randomized, placebo-controlled trial","volume":"10","author":"J Kamgno","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0010497.ref012","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0140-6736(96)11094-1","article-title":"Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection","volume":"350","author":"J Gardon","year":"1997","journal-title":"Lancet"},{"key":"pntd.0010497.ref013","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1586\/ecp.11.72","article-title":"Pharmacokinetic variability of anthelmintics: implications for the treatment of neurocysticercosis","volume":"5","author":"H. Jung-Cook","year":"2012","journal-title":"Expert Rev Clin Pharmacol"},{"key":"pntd.0010497.ref014","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4269\/ajtmh.2000.63.270","article-title":"Effect of dose increase or cimetidine co-administration on albendazole bioavailability","volume":"63","author":"HG Schipper","year":"2000","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0010497.ref015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.2042-7158.1998.tb03303.x","article-title":"Absorption studies of albendazole and some physicochemical properties of the drug and its metabolite albendazole sulphoxide","volume":"50","author":"H Jung","year":"1998","journal-title":"J Pharm Pharmacol"},{"key":"pntd.0010497.ref016","first-page":"267","article-title":"Effect of gastric pH on the bioavailability of albendazole in rabbits","volume":"4","author":"N Kohri","year":"1998","journal-title":"Pharm Pharmacol Commun"},{"key":"pntd.0010497.ref017","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1093\/cid\/ciz085","article-title":"Albendazole sulfoxide plasma levels and efficacy of antiparasitic treatment in patients with parenchymal neurocysticercosis","volume":"69","author":"G Arroyo","year":"2019","journal-title":"Clin Infect Dis"},{"key":"pntd.0010497.ref018","doi-asserted-by":"crossref","first-page":"e494","DOI":"10.1093\/cid\/ciaa989","article-title":"Efficacy and safety of albendazole in hookworm-infected preschool-aged children, school-aged children, and adults in C\u00f4te d\u2019Ivoire: a phase 2 randomized, controlled dose-finding trial","volume":"73","author":"C Patel","year":"2021","journal-title":"Clin Infect Dis"},{"key":"pntd.0010497.ref019","doi-asserted-by":"crossref","first-page":"e25003","DOI":"10.1371\/journal.pone.0025003","article-title":"Efficacy of single-dose and triple-dose albendazole and mebendazole against soil-transmitted helminths and Taenia spp.: a randomized controlled trial","volume":"6","author":"P Steinmann","year":"2011","journal-title":"PLoS One"},{"key":"pntd.0010497.ref020","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/jnnp.62.6.659","article-title":"Albendazole therapy for subarachnoid cysticerci: clinical and neuroimaging analysis of 17 patients","volume":"62","author":"OH Del Brutto","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"pntd.0010497.ref021","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1128\/CMR.15.4.747-756.2002","article-title":"Current consensus guidelines for treatment of neurocysticercosis","volume":"15","author":"HH Garc\u00eda","year":"2002","journal-title":"Clin Microbiol Rev"},{"key":"pntd.0010497.ref022","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1017\/S0022149X17000426","article-title":"Efficacy of single-dose 500 mg mebendazole in soil-transmitted helminth infections: a review","volume":"92","author":"J Mrus","year":"2018","journal-title":"J Helminthol"},{"key":"pntd.0010497.ref023","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.pt.2012.02.004","article-title":"Paradigm lost: how parasite control may alter pattern and process in human helminthiases","volume":"28","author":"MG Bas\u00e1\u00f1ez","year":"2012","journal-title":"Trends Parasitol"},{"key":"pntd.0010497.ref024","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00228-002-0488-8","article-title":"Effect of gender in the disposition of albendazole metabolites in humans","volume":"58","author":"A Mirfazaelian","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"pntd.0010497.ref025","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1179\/000349803235001697","article-title":"The co-administration of ivermectin and albendazole\u2014safety, pharmacokinetics and efficacy against Onchocerca volvulus","volume":"97","author":"K Awadzi","year":"2003","journal-title":"Ann Trop Med Parasitol"},{"key":"pntd.0010497.ref026","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/BF00540964","article-title":"Increased systemic availability of albendazole when taken with a fatty meal","volume":"34","author":"H Lange","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"key":"pntd.0010497.ref027","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1742-7843.2005.pto_172.x","article-title":"Influence of a Mexican diet on the bioavailability of albendazole","volume":"97","author":"SS Mares","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"pntd.0010497.ref028","doi-asserted-by":"crossref","first-page":"e0005945","DOI":"10.1371\/journal.pntd.0005945","article-title":"Assessment of serum pharmacokinetics and urinary excretion of albendazole and its metabolites in human volunteers","volume":"12","author":"L Ceballos","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0010497.ref029","doi-asserted-by":"crossref","first-page":"e0043221","DOI":"10.1128\/AAC.00432-21","article-title":"Assessment of diet-related changes on albendazole absorption, systemic exposure, and pattern of urinary excretion in treated human volunteers","volume":"65","author":"L Ceballos","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"pntd.0010497.ref030","doi-asserted-by":"crossref","first-page":"e0007325","DOI":"10.1371\/journal.pntd.0007325","article-title":"Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in C\u00f4te d\u2019Ivoire","volume":"13","author":"C Edi","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0010497.ref031","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/clpt.1990.38","article-title":"Albendazole treatment of echinococcosis in humans: effects on microsomal metabolism and drug tolerance","volume":"47","author":"U Steiger","year":"1990","journal-title":"Clin Pharmacol Ther"},{"key":"pntd.0010497.ref032","first-page":"416","article-title":"The metabolism of albendazole in the isolated perfused intestine of rats","volume":"99","author":"A Lawrenz","year":"1992","journal-title":"Dtsch Tierarztl Wochenschr"},{"key":"pntd.0010497.ref033","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1179\/000349804225021370","article-title":"The safety, tolerability and pharmacokinetics of levamisole alone, levamisole plus ivermectin, and levamisole plus albendazole, and their efficacy against Onchocerca volvulus","volume":"98","author":"K Awadzi","year":"2004","journal-title":"Ann Trop Med Parasitol"},{"key":"pntd.0010497.ref034","first-page":"203","article-title":"The chemotherapy of onchocerciasis XVII. A clinical evaluation of albendazole in patients with onchocerciasis; effects of food and pretreatment with ivermectin on drug response and pharmacokinetics","volume":"45","author":"K Awadzi","year":"1994","journal-title":"Trop Med Parasitol"},{"key":"pntd.0010497.ref035","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jpba.2004.02.022","article-title":"Simultaneous determination of albendazole and its major active metabolite in human plasma using a sensitive and specific liquid chromatographic-tandem mass spectrometric method","volume":"35","author":"X Chen","year":"2004","journal-title":"J Pharm Biomed Anal"},{"key":"pntd.0010497.ref036","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jpba.2017.12.037","article-title":"LC\u2013MS\/MS method for simultaneous determination of diethylcarbamazine, albendazole and albendazole metabolites in human plasma: application to a clinical pharmacokinetic study","volume":"151","author":"YS Chhonker","year":"2018","journal-title":"J Pharm Biomed Anal"},{"key":"pntd.0010497.ref037","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00228-009-0683-y","article-title":"Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers","volume":"65","author":"N Corti","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"pntd.0010497.ref038","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/BF00278590","article-title":"Albendazole kinetics in patients with echinococcosis: delayed absorption and impaired elimination in cholestasis","volume":"38","author":"J Cotting","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"pntd.0010497.ref039","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/00498259109039463","article-title":"Comparative enantioselectivity in the sulphoxidation of albendazole in man, dogs and rats","volume":"21","author":"P Delatour","year":"1991","journal-title":"Xenobiotica"},{"key":"pntd.0010497.ref040","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/0378-4347(91)80131-U","article-title":"Rapid and sensitive method for the determination of albendazole and albendazole sulphoxide in biological fluids","volume":"566","author":"PE Hoaksey","year":"1991","journal-title":"J Chromatogr"},{"key":"pntd.0010497.ref041","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/jac\/dkac020","article-title":"Pharmacokinetic modelling and simulation to optimize albendazole dosing in hookworm- or Trichuris trichiura-infected infants to adults","volume":"77","author":"D Hofmann","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"pntd.0010497.ref042","doi-asserted-by":"crossref","first-page":"ciaa1202","DOI":"10.1093\/cid\/ciaa1202","article-title":"Pharmacokinetic and safety study of co-administration of albendazole, diethylcarbamazine, ivermectin and azithromycin for the integrated treatment of Neglected Tropical Diseases","author":"LN John","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pntd.0010497.ref043","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/j.1552-4604.1992.tb03783.x","article-title":"Clinical pharmacokinetics of albendazole in patients with brain cysticercosis","volume":"32","author":"H Jung","year":"1992","journal-title":"J Clin Pharmacol"},{"key":"pntd.0010497.ref044","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00045391-199701000-00005","article-title":"Clinical pharmacokinetics of albendazole in children with neurocysticercosis","volume":"4","author":"H Jung","year":"1997","journal-title":"Am J Ther"},{"key":"pntd.0010497.ref045","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0731-7085(02)00382-5","article-title":"HPLC assay for albendazole and metabolites in human plasma for clinical pharmacokinetic studies","volume":"30","author":"D Kitzman","year":"2002","journal-title":"J Pharm Biomed Anal"},{"key":"pntd.0010497.ref046","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1365-2125.2010.03874.x","article-title":"Albendazole-praziquantel interaction in healthy volunteers: kinetic disposition, metabolism and enantioselectivity","volume":"71","author":"RM Lima","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"pntd.0010497.ref047","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/BF00608219","article-title":"Pharmacokinetics of albendazole in man","volume":"30","author":"SE Marriner","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"pntd.0010497.ref048","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0001-706X(02)00096-7","article-title":"Albendazole-soybean oil emulsion for the treatment of human cystic echinococcosis: evaluation of bioavailability and bioequivalence","volume":"83","author":"W Mingjie","year":"2002","journal-title":"Acta Trop"},{"key":"pntd.0010497.ref049","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/bdd.327","article-title":"Dose dependent pharmacokinetics of albendazole in human","volume":"23","author":"A Mirfazaelian","year":"2002","journal-title":"Biopharm Drug Dispos"},{"key":"pntd.0010497.ref050","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/bdd.355","article-title":"Time dependent pharmacokinetics of albendazole in human","volume":"24","author":"A Mirfazaelian","year":"2003","journal-title":"Biopharm Drug Dispos"},{"key":"pntd.0010497.ref051","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.trstmh.2005.05.017","article-title":"Assessments of pharmacokinetic drug interactions and tolerability of albendazole, praziquantel and ivermectin combinations","volume":"100","author":"K Na-Bangchang","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"pntd.0010497.ref052","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4269\/ajtmh.2002.66.260","article-title":"Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability","volume":"66","author":"J Nagy","year":"2002","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0010497.ref053","doi-asserted-by":"crossref","first-page":"664465","DOI":"10.3389\/fphar.2021.664465","article-title":"High-fat breakfast increases bioavailability of albendazole compared to low-fat breakfast: single-dose study in healthy subjects","volume":"12","author":"D Ochoa","year":"2021","journal-title":"Front Pharmacol"},{"key":"pntd.0010497.ref054","first-page":"643","article-title":"Pharmacokinetics of albendazole in children with hydatid disease","volume":"70","author":"GB Okelo","year":"1993","journal-title":"East Afr Med J"},{"key":"pntd.0010497.ref055","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1179\/000349804225003398","article-title":"Pharmacokinetic investigation of albendazole and praziquantel in Thai children infected with Giardia intestinalis","volume":"98","author":"K Pengsaa","year":"2004","journal-title":"Ann Trop Med Parasitol"},{"key":"pntd.0010497.ref056","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jpha.2016.02.002","article-title":"Liquid chromatography\u2014tandem mass spectrometry method for simultaneous determination of albendazole and albendazole sulfoxide in human plasma for bioequivalence studies","volume":"6","author":"DM Rathod","year":"2016","journal-title":"J Pharm Anal"},{"key":"pntd.0010497.ref057","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1128\/AAC.48.3.1051-1054.2004","article-title":"Relative bioavailability of three newly developed albendazole formulations: a randomized crossover study with healthy volunteers","volume":"48","author":"IM Rigter","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"pntd.0010497.ref058","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jchromb.2003.10.040","article-title":"Albendazole sulphoxide concentrations in plasma of endemic normals from a lymphatic filariasis endemic region using liquid chromatography","volume":"799","author":"R Sarin","year":"2004","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"pntd.0010497.ref059","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02489-18","article-title":"Pharmacokinetics of albendazole, albendazole sulfoxide, and albendazole sulfone determined from plasma, blood, dried-blood spots, and Mitra samples of hookworm-infected adolescents","volume":"63","author":"JD Schulz","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"pntd.0010497.ref060","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1179\/000349802125001663","article-title":"The pharmacokinetics, safety and tolerability of the co-administration of diethylcarbamazine and albendazole","volume":"96","author":"RK Shenoy","year":"2002","journal-title":"Ann Trop Med Parasitol"},{"key":"pntd.0010497.ref061","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/civ882","article-title":"Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of Bancroftian filariasis","volume":"62","author":"EK Thomsen","year":"2016","journal-title":"Clin Infect Dis"},{"key":"pntd.0010497.ref062","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2165\/00003495-200262100-00005","article-title":"Food-drug interactions","volume":"62","author":"LE Schmidt","year":"2002","journal-title":"Drugs"},{"key":"pntd.0010497.ref063","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0304-4017(96)01118-1","article-title":"Modified plasma and abomasal disposition of albendazole in nematode-infected sheep","volume":"69","author":"LI Alvarez","year":"1997","journal-title":"Vet Parasitol"},{"key":"pntd.0010497.ref064","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.vetpar.2007.02.026","article-title":"Mouflon (Ovis musimon) dicrocoeliosis: effects of parasitosis on the activities of biotransformation enzymes and albendazole metabolism in liver","volume":"146","author":"L Sk\u00e1lov\u00e1","year":"2007","journal-title":"Vet Parasitol"},{"key":"pntd.0010497.ref065","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0007-1935(05)80213-1","article-title":"Plasma profiles of albendazole metabolites after administration of netobimin and albendazole in sheep: effects of parasitism and age","volume":"149","author":"QA McKellar","year":"1993","journal-title":"Br Vet J"},{"key":"pntd.0010497.ref066","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.4269\/ajtmh.2007.76.1153","article-title":"Pharmacokinetics of azithromycin and the combination of ivermectin and albendazole when administered alone and concurrently in healthy volunteers","volume":"76","author":"GW Amsden","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0010497.ref067","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2125.2005.02529.x","article-title":"Clinically relevant drug interactions with antiepileptic drugs","volume":"61","author":"E. Perucca","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"pntd.0010497.ref068","doi-asserted-by":"crossref","first-page":"e0006003","DOI":"10.1371\/journal.pntd.0006003","article-title":"Albendazole and ivermectin for the control of soil-transmitted helminths in an area with high prevalence of Strongyloides stercoralis and hookworm in northwestern Argentina: A community-based pragmatic study","volume":"11","author":"A Echaz\u00fa","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0010497.ref069","doi-asserted-by":"crossref","first-page":"e1002839","DOI":"10.1371\/journal.pmed.1002839","article-title":"The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: a multicenter, open-label, cluster-randomized study","volume":"16","author":"GJ Weil","year":"2019","journal-title":"PLoS Med"},{"key":"pntd.0010497.ref070","doi-asserted-by":"crossref","first-page":"E9712","DOI":"10.1073\/pnas.1710845114","article-title":"Albendazole and antibiotics synergize to deliver short-course anti-Wolbachia curative treatments in preclinical models of filariasis","volume":"114","author":"JD Turner","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pntd.0010497.ref071","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3109\/00498259509061863","article-title":"Small intestinal sulphoxidation of albendazole","volume":"25","author":"C Villaverde","year":"1995","journal-title":"Xenobiotica"},{"key":"pntd.0010497.ref072","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/11319320-000000000-00000","article-title":"Multiple peaking phenomena in pharmacokinetic disposition","volume":"49","author":"NM Davies","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"pntd.0010497.ref073","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s40262-016-0467-3","article-title":"Lack of clinical pharmacokinetic studies to optimize the treatment of neglected tropical diseases: a systematic review","volume":"56","author":"L Verrest","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"pntd.0010497.ref074","doi-asserted-by":"crossref","first-page":"e0009888","DOI":"10.1371\/journal.pntd.0009888","article-title":"Individual responses to a single oral dose of albendazole indicate reduced efficacy against soil-transmitted helminths in an area with high drug pressure","volume":"15","author":"M Walker","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0010497.ref075","doi-asserted-by":"crossref","first-page":"5","DOI":"10.12688\/wellcomeopenres.17468.1","article-title":"Improving anthelmintic treatment for schistosomiasis and soil-transmitted helminthiases through sharing and reuse of individual participant data","volume":"7","author":"M Walker","year":"2022","journal-title":"Wellcome Open Res"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0010497","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0010497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T13:34:02Z","timestamp":1668432842000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0010497"}},"subtitle":[],"editor":[{"given":"Husain","family":"Poonawala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":75,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0010497","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.05.18.22275185","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]}}}